The lifetime risk of carriers for developing ovarian cancer is high, 35–60% for BRCA-1 mutation carriers and 10–20% for BRCA-2 mutation carriers, in contrast to the 1.8% lifetime risk of the general population (Ford et al, 1995; Antoniou et al, 2003). This evidence concerns the gene BRCA2 and ovarian carcinoma.